Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

ClinicalTrials.gov

Author's Posts:
Combination 5-FU / Calcipotriene Cream for SCCIS/SCC
Condition:   Squamous Cell Carcinoma
Interventions:   Drug: Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream;   Drug: Nourivan Base Cream
Sponsor:   Carilion Clinic
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 10, 2021 / by / in
Pilot Evaluation of a Healthy Lifestyle Intervention for Adolescent and Young Adult Survivors of Pediatric Cancer
Condition:   Pediatric Cancer
Interventions:   Behavioral: Healthy Lifestyles;   Behavioral: Education-Only Control
Sponsor:   Johns Hopkins All Children’s Hospital
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 10, 2021 / by / in
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Conditions:   Advanced Solid Tumor;   NSCLC;   Melanoma;   Cervical Cancer;   Multiple Myeloma;   Lymphoma, Non-Hodgkin;   DLBCL;   Gastric Cancer;   Gastroesophageal Junction Adenocarcinoma;   Esophageal Cancer
Interventions:   Drug: AB308;   Drug: Zimberelimab
Sponsor:   Arcus Biosciences, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2021 / by / in
Vascular Anomaly Pathology and Genomics Biopsy Study
Conditions:   Vascular Malformations;   Vascular Anomaly;   Hemangioma;   Arteriovenous Malformations;   Venous Malformation;   Klippel Trenaunay Syndrome;   Lymphatic Malformation
Intervention:   Procedure: Percutaneous Vascular Anomaly/Malformation Biopsy
Sponsor:   Mayo Clinic
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2021 / by / in
Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study
Conditions:   Advanced Pancreatic Adenocarcinoma;   Pancreatic Adenocarcinoma;   Stage III Pancreatic Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8
Interventions:   Other: Educational Intervention;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Resistance Training
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2021 / by / in
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Ensartinib;   Drug: Pemetrexed
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2021 / by / in
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Condition:   Pancreatic Ductal Adenocarcinoma
Intervention:   Diagnostic Test: ultrasound
Sponsor:   Memorial Sloan Kettering Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2021 / by / in
Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients
Conditions:   Breast Cancer;   Depression, Anxiety;   Mindfulness;   Sleep Disturbance
Interventions:   Behavioral: Mindfulness;   Behavioral: Control group
Sponsor:   Stanford University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2021 / by / in
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
Conditions:   Recurrent Head and Neck Squamous Cell Carcinoma;   Unresectable Head and Neck Squamous Cell Carcinoma
Interventions:   Other: Hafnium Oxide-containing Nanoparticles NBTXR3;   Procedure: Intensity-Modulated Proton Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Radiation Therapy
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2021 / by / in
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
Conditions:   Renal Cell Carcinoma;   Gastric Cancer;   Metastatic Breast Cancer;   Small-cell Lung Cancer
Intervention:   Drug: HC-5404-FU
Sponsors:   HiberCell, Inc.;   Covance
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 9, 2021 / by / in